AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Neurosciencenews

Published November 9, 2026 · Updated November 10, 2026

Psychedelics Linked to Lower Anxiety and Depression in Young Adults

Read the full story at Neurosciencenews

Classic Psychedelic Users: Individuals who used 5-HT2A receptor agonists, including psilocybin (“ magic mushrooms ”), LSD, DMT, or mescaline. Non.

Post on X

Share this story

Surfaced by this Google Alert

Magic mushrooms